Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
Símbolo de cotizaciónKRYS
Nombre de la empresaKrystal Biotech Inc
Fecha de salida a bolsaSep 20, 2017
Director ejecutivoKrishnan (Krish S)
Número de empleados275
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 20
Dirección2100 Wharton St Ste 701
CiudadPITTSBURGH
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal15203
Teléfono14125865830
Sitio Webhttps://www.krystalbio.com/
Símbolo de cotizaciónKRYS
Fecha de salida a bolsaSep 20, 2017
Director ejecutivoKrishnan (Krish S)
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos